U.S. court rules in favor of Mylan over Biogen’s key MS drug patent
(Reuters) – A U.S. district court on Thursday ruled in favor of generic drugmaker Mylan NV in a patent dispute over Biogen Inc’s blockbuster multiple sclerosis drug, Tecfidera, sending Biogen’s shares down nearly 6%. Tecfidera has been Biogen’s main growth driver since it was launched in 2013, generating sales of $4.43 billion in 2019, accounting … Read more